vs
Dermata Therapeutics, Inc.(DRMA)与法拉第未来(FFAI)财务数据对比。点击上方公司名可切换其他公司
法拉第未来的季度营收约是Dermata Therapeutics, Inc.的1.4倍($129.0K vs $92.8K),Dermata Therapeutics, Inc.净利率更高(-1853.3% vs -26011.6%,领先24158.4%),Dermata Therapeutics, Inc.同比增速更快(531.8% vs -45.1%)
Dermata Therapeutics是一家临床阶段生物制药公司,专注于开发针对痤疮、银屑病、炎症性皮肤病等皮肤科疾病的创新靶向疗法,主要服务美国市场的患者与医疗从业者,推进在研管线试验以满足皮肤科领域未被满足的医疗需求。
法拉第未来是2014年成立的美国科技企业,总部位于加利福尼亚州洛杉矶,核心业务为研发电动汽车,2023年正式投入量产,产品在中美两国市场销售。截至2025年1月,该公司累计交付16辆汽车。2024年末完成两轮合计6000万美元融资后,法拉第未来宣布将转型销售贴牌中国厢式车。
DRMA vs FFAI — 直观对比
营收规模更大
FFAI
是对方的1.4倍
$92.8K
营收增速更快
DRMA
高出576.9%
-45.1%
净利率更高
DRMA
高出24158.4%
-26011.6%
损益表 — Q3 FY2023 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $92.8K | $129.0K |
| 净利润 | $-1.7M | $-33.6M |
| 毛利率 | — | -12111.6% |
| 营业利润率 | -1953.3% | -25041.9% |
| 净利率 | -1853.3% | -26011.6% |
| 营收同比 | 531.8% | -45.1% |
| 净利润同比 | 29.1% | 72.3% |
| 每股收益(稀释后) | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
DRMA
FFAI
| Q4 25 | — | $129.0K | ||
| Q1 25 | — | $316.0K | ||
| Q4 24 | — | $235.0K | ||
| Q2 24 | — | $293.0K | ||
| Q4 23 | — | $233.0K | ||
| Q3 23 | $92.8K | $551.0K | ||
| Q2 23 | $31.1K | $0 | ||
| Q1 23 | $37.5K | $0 |
净利润
DRMA
FFAI
| Q4 25 | — | $-33.6M | ||
| Q1 25 | — | $-10.3M | ||
| Q4 24 | — | $-121.3M | ||
| Q2 24 | — | $-108.7M | ||
| Q4 23 | — | $-83.8M | ||
| Q3 23 | $-1.7M | $-78.0M | ||
| Q2 23 | $-1.7M | $-124.9M | ||
| Q1 23 | $-2.2M | $-145.0M |
毛利率
DRMA
FFAI
| Q4 25 | — | -12111.6% | ||
| Q1 25 | — | -6666.1% | ||
| Q4 24 | — | -8801.7% | ||
| Q2 24 | — | -7057.0% | ||
| Q4 23 | — | -8424.9% | ||
| Q3 23 | — | -2827.6% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
营业利润率
DRMA
FFAI
| Q4 25 | — | -25041.9% | ||
| Q1 25 | — | -13870.6% | ||
| Q4 24 | — | -12899.6% | ||
| Q2 24 | — | -17272.7% | ||
| Q4 23 | — | -29090.1% | ||
| Q3 23 | -1953.3% | -12059.3% | ||
| Q2 23 | -5579.4% | — | ||
| Q1 23 | -6067.3% | — |
净利率
DRMA
FFAI
| Q4 25 | — | -26011.6% | ||
| Q1 25 | — | -3252.5% | ||
| Q4 24 | — | -51599.6% | ||
| Q2 24 | — | -37093.9% | ||
| Q4 23 | — | -35964.4% | ||
| Q3 23 | -1853.3% | -14164.4% | ||
| Q2 23 | -5479.4% | — | ||
| Q1 23 | -5967.3% | — |
每股收益(稀释后)
DRMA
FFAI
| Q4 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $6.6M | $34.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.4M | $-27.3M |
| 总资产 | $7.3M | $277.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
DRMA
FFAI
| Q4 25 | — | $34.9M | ||
| Q1 25 | — | $9.5M | ||
| Q4 24 | — | $7.1M | ||
| Q2 24 | — | $793.0K | ||
| Q4 23 | — | $1.9M | ||
| Q3 23 | $6.6M | $6.7M | ||
| Q2 23 | $8.4M | $17.9M | ||
| Q1 23 | $8.8M | $31.8M |
股东权益
DRMA
FFAI
| Q4 25 | — | $-27.3M | ||
| Q1 25 | — | $139.8M | ||
| Q4 24 | — | $115.0M | ||
| Q2 24 | — | $148.7M | ||
| Q4 23 | — | $228.2M | ||
| Q3 23 | $6.4M | $261.8M | ||
| Q2 23 | $8.0M | $277.7M | ||
| Q1 23 | $8.1M | $255.8M |
总资产
DRMA
FFAI
| Q4 25 | — | $277.9M | ||
| Q1 25 | — | $410.6M | ||
| Q4 24 | — | $425.4M | ||
| Q2 24 | — | $457.9M | ||
| Q4 23 | — | $530.5M | ||
| Q3 23 | $7.3M | $579.5M | ||
| Q2 23 | $8.7M | $567.5M | ||
| Q1 23 | $9.3M | $575.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | — | $-28.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-29.5M |
| 自由现金流率自由现金流/营收 | — | -22886.8% |
| 资本支出强度资本支出/营收 | — | 867.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-91.3M |
8季度趋势,按日历期对齐
经营现金流
DRMA
FFAI
| Q4 25 | — | $-28.4M | ||
| Q1 25 | — | $-20.3M | ||
| Q4 24 | — | $-18.4M | ||
| Q2 24 | — | $-14.4M | ||
| Q4 23 | — | $-37.8M | ||
| Q3 23 | — | $-79.7M | ||
| Q2 23 | — | $-57.7M | ||
| Q1 23 | $-1.6M | $-103.0M |
自由现金流
DRMA
FFAI
| Q4 25 | — | $-29.5M | ||
| Q1 25 | — | $-21.9M | ||
| Q4 24 | — | $-25.3M | ||
| Q2 24 | — | $-14.6M | ||
| Q4 23 | — | $-58.1M | ||
| Q3 23 | — | $-94.7M | ||
| Q2 23 | — | $-66.7M | ||
| Q1 23 | — | $-119.9M |
自由现金流率
DRMA
FFAI
| Q4 25 | — | -22886.8% | ||
| Q1 25 | — | -6918.7% | ||
| Q4 24 | — | -10770.6% | ||
| Q2 24 | — | -4993.5% | ||
| Q4 23 | — | -24923.2% | ||
| Q3 23 | — | -17181.1% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
资本支出强度
DRMA
FFAI
| Q4 25 | — | 867.4% | ||
| Q1 25 | — | 496.2% | ||
| Q4 24 | — | 2945.1% | ||
| Q2 24 | — | 88.4% | ||
| Q4 23 | — | 8696.6% | ||
| Q3 23 | — | 2723.4% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图